Company Data
Editas Medicine Inc.
Ticker
EDIT
Current Price
$2.06 -35.62%
Market Cap
$170.0M
Price Target
Refer to Report
Volume
16.4M
52wk Range
$1.12 - $11.58
Overview
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company’s only operating segment is developing and commercializing genome editing technology.